Pgf&#39; 3 &#39;analogs

ABSTRACT

This disclosure relates to prostaglandins of the PG3 series including PGE3, PGF3 , PGF3 , PGA3, and PGB3, to various analogs of those in racemic form, and to novel processes for making those. This disclosure also relates to certain fluorine and alkyl substituted analogs and certain acetylenic analogs of PGE3, PGF3 , PGF3 , PGA3, and PGB3 in both racemic and optically active form, and to processes for making those. These various analogs are useful for the same pharmacological purposes as the known optically active forms of PGE3, PGF3 , PGF3 , PGA3, and PGB3, including anti-ulcer, inhibition of platelet aggregation, increase of nasal patency, labor inducement, fertility control, and wound healing.

United States Patent [191 Axen Nov. 18, 1975 PGF ANALOGS 3.804.879 4/1974 Bergstrom et a1. 260/468 [75] Inventor: Udo F. Axen, Comstock, Mich.

[73] Assignee: The Upjohn Company, Kalamazoo, Primary E.\'aminerRobert Gerstl Mich.

[22] Filed: Nov. 5, 1973 Appl. No.: 412,687

Related US. Application Data Continuation-in-part of Ser. No. 112,032, Feb. 2, 1971, Pat. No. 3,775,462, which is a continuation-in-part of Ser. No. 30,312, April 20, 1970, abandoned.

U.S. Cl... 260/468 D; 260/211 R; 260/2472 R;

260/268 R; 260/293.65; 2150/3212; 260/408; 260/410; 260/410 5; 260/4l0.9 R; 260/413; 260/434; 260/448 R; 260/424.9; 260/501.1;

1m. c1. c07c 61/38; c07c 69/74 Field of Search 260/468 D, 514 D References Cited UNITED STATES PATENTS 10/1973 Pike et a1 260/468 [57] ABSIRACT This disclosure relates to prostaglandins of the-P6 series including PGE PGF a, PGF B, PGA and l3 Claims, No Drawings 1 PGF ANALOGS CROSS REFERENCE To RELAT'EDAP ucATIoN This application is a continuation-in-part of copending application Ser. No. 112,032, filed Feb. 2, 1971,

now US. Pat. No. 3,775,462, which i'sia continuationin-part of copending application Sen No. 30,312, filed Pl 1970, and now abandoned.

BRIEF DESCRIPTION "OF THE INVENTION:

This invention relates to compositions of matter, and to methods and intermediates for producing them. In particular, the several aspects of this invention relate to racemic prostaglandin E (PGE racemic prostaglandin F (PGF and PGF B racemic prostaglandin A; P G A prostaglandin E (PO3 to -the corresponding acetylenic pr'ostaglandins, 5 ,6,l7,1,8-dehy-.

dro-PGE 5,6 ,17, 18?;1ehydro-PGFQ, 5,6,17,18-dehydehydro-PGB to analogs of those. prostaglandins and 5,6,l7,l8-dehydro-prostaglandins; to processes for producing racemic PGE PGFga PGF p PGA PGB the corresponding 5,6,17,18-dehydro-prostaglandins, and the analogs thereof; to processes for resolving the racemates into the dand'lforms; and to chemical intermediates useful in those methods.

Optically active (the natural or d-configuration') is akri'ov'vn substance. Bergstrom, Science 157,

382(1967); Samuelson, J. Amer. Chem. Soc, 85, 1878 (1963). Optically active FOR, (02 and B), obtained by theborohyd'ride reduction of optically active PGE is also a known substance; SamuelsomBidchemica Biophysiciz Acla, '8 4, 707 (l96'4); soIalso is optically active PGA iBritishSpecification No. 1,097,533. Optically active PGE optically active PGF and optically active PGF fiare also T disclosed in British specification NO. 1,049,544. 1 i

The prior an methods for producing prostaglandin s are costly and difficult, the necessary biological materials are limited, and the methoclsare not adaptable to I production of a wide variety of prostaglandin interme diate's and analogs.

It is the purpose of this invention'to provide pro-' cesses for the production of compounds with prostaglandinlike activity in substantial amounts and at reasonable cost. The useful compounds produced according to the processes of this, invention comprise racemic PGE racemic PGF racemic PGF racemic PGA racemic PO8 the corresponding 5,6,17,18- dehydro-prostaglandins, and other hitherto unavailable racemic and optically active analogs thereof such as the enantiomorphs (d and 1- forms) of P68 and the 5,6,17, l 8-dehydro compounds.

PGE has the following structure:

PGF B has the following structure:

the following structure:

, The above formulas. represent the natural configura- PGA and tion. Racemic PGE PGF PGF;, 3 PGB are each represented by the combination of one of the above formulas and the mirror image (enantiomorph) of that formula. See Nature, 2 l 2 38 1966) for discussion of the stereochemistry of the prostaglandins.

In formulas I, ll, Ill, IV, and V, as well as in the formulas given hereinafter, broken line attachments to the cyclopentane ring indicate substituents in alpha config-, uration, i.e., below the plane of the cyclopentane ring. Heavysolid line attachments to the cyclopentane ring indicate substituents in beta configuration, i.e., above the plane of the cyclopentane ring.

PGE PGF;, PGF PGA and P08 are derivatives of prostanoic acid which has the following structure and atom numbering:

A systematic name for iso-prostanoic acid is 7-[(2,B- octyl)-cyclopent-lB-yllheptanoic acid.

Prostaglandin E and its analogs and isomers produced according to the processes of this invention are represented by the formula:

wherein R is hydrogen, alkyl of one to 8 carbon atoms,

inclusive, cycloalkyl of 3 to 10 carbon atoms, inclusive, aralkyl of 7 to 12 carbon atoms, inclusive, phenyl, phenyl substituted with one to 3 chloro or alkyl of one to 4 carbon atoms, inclusive, or ethyl substituted in the flp0'sition with 3 chloro, 2 or'3 bromo, or 1, 2, or 3 iodo; wherein R is alkyl of one to 4 carbon atoms, inclusive, substituted with zero to 3 fiuoro; wherein R and R are hydrogen or alkyl of one to 4 carbon atoms, inclusive; wherein n is an integer of one to 4, inclusive, wherein A is alkylene of oneto lOcarbon atoms, inclusive, substituted with zero to 2 fluoro, and with one to 5 carbon atoms, inclusive, between ,COOR and I and pharmacologically acceptable salts thereof VII wherein R is hydrogen. v

Prostaglandin F and'its analogs and isomers produced according to the processes of this invention are represented by the formula: I

wherein R R R R and A are as defined above for formula Vllle, and pharmacologically acceptable salts thereof when R is hydrogen.

Prostaglandin A and its analogs and isomers produced according to the processes of this invention are represented by the formula:

wherein R R R R and A are as defined above for v formula Vllle, and the pharrnacologically acceptable salts thereof wherein R is hydrogen.

Prostaglandin B and its analogs and isomers (including its enantiomorphs) produced according to the processes of this invention are represented by the formula:

H H C=C CH A CO R o 2 0 I C=C OHH H H C C=C Xle R3 II Zn R2 wherein R R R R and A are defined above for formula VlIIe, and pharmacologically acceptable salts thereof wherein R is hydrogen.

The wavy line, as used above, and elsewhere herein, includes both configurations, i.e., alpha and beta, or endo or exo. The word racemic indicates an equal mixture of a compound of the formula shown, which is the natural configuration, and its enantiomorph.

Compounds of formula Vllle, IXe, Xe, and Xle have their counterpart where the cis-ethylenes are dehydro, i.e., ethynylene. These dehydro analogs here designated as Vllld, IXd, Xd, and Xld, are intermediates, as will be shown, for making the compounds of formulas VIIIe, lXe, Xe, and Xle. Racemic dehydro compounds give racemic final products. An enantiomorph of the dehydro compound (the configuration as shown or the mirror image thereof) gives the corresponding enantiomorph of the final compound.

Also included in formulas VIII, IX, X, and XI are separate isomers wherein the side chain hydroxy is in R or S configuration. All of the compounds encompassed by formulas VIII, IX, and X have the trans Cl-I=C- R CR OH- side chain attached in beta configuration.

Formulas VlIle, IXe, Xe, and Xle represent PGE PGF PGA and PGB respectively, when in these formulas R R and R are each hydrogen, n is 1, R is ethyl, A is trimethylene, the attachment of --CH- Cl-I=Cl-IACOOR to the cyclopentane ring is in alpha configuration, and the configuration of the side chain hydroxy is S.

With regard to formulas VIII to XI, inclusive, examples of alkyl of one to 4 carbon atoms, inclusive, are methyl, ethyl, propyl, butyl, and isomeric forms thereof. Examples of alkyl of one to 8 carbon atoms, inclusive, are those given above, and pentyl, hexyl, heptyl, octyl, and isomeric forms thereof. Examples of alkyl of one to 10 carbon atoms, inclusive, are those given above, and nonyl, decyl, and isomeric forms thereof. Examples of cycloalkyl of 3 to 10 carbon atoms, inclusive, which includes alkyl-substituted cycloalkyl, are cyclopropyl, Z-methylcyclopropyl, 2,2- dimethylcyclopropyl, 2,3-diethylcyclopropyl, 2-butylcyclopropyl, cyclobutyl, Z-methylcyclobutyl, 3-propylcyclobutyl, 2,3,4-triethylcyclobutyl, cyclopentyl, 2,2- dimethylcyclopentyl, 3-pentylcyclopentyl, 3-tert-butylcyclopentyl, cyclohexyl, 4-tert-butylcyclohexyl, 3-isopropylcyclohexyl, 2,2-dimethylcyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, and cyclodecyl. Examples of aralkyl of 7 to 12 carbon atoms, inclusive, are ben-' zyl, phenethyl, l-phenethyl, l-phenylethyl, Z-phenylpropyl, 4-phenylbutyl, 3-phenylbutyl, 2-(l-naphthylethyl), and I-(Z-naphthylmethyl). Examples of phenyl substituted by one to 3 chloro or alkyl or one to 4 carbon atoms, inclusive, are p-chlorophenyl, mchlorophenyl, o-chlorophenyl, 2,4-dichlorophenyl, 2,4,6-trichlorophenyl, p-tolyl, m-tolyl, o-tolyl, p-ethylphenyl, p-tert-butylphenyl, 2,5-dimethylphenyl, 4- chloro-2-methylphenyl, and 2,4-dichloro-3-methylphenyl.

Examples of alkylene of one to 10 carbon atoms, inclusive, are methylene, ethylene, trimethylene, tetramethylene, pentamethylene, and isomeric branched chain forms thereof, l-, 2-, and 3-methylpentamethylene, l-, 2-, 3-ethylpentamethylene, 1-, 2-, and 3- propylpentamethylene, l-, 2-, and 3-butylpentamethylene, and l-, 2-,.and 3-pentylpentamethylene.

Examples of alkyl of one to 4 carbon atoms, inclusive, substituted with one to 3 fluoro, are 2-fluoroethyl,

Examples of alkylene of one to 10 carbon atoms, in-

, clusive, substituted with one or 2 fluoro, have the for- PGE PGF PGF PGA ,and PGB and their esters and pharmacologically acceptable salts, are extremely potent in causing various biological responses. For that reason, these compounds are useful for pharmacological purposes. See, for example, Bergstrom et al., Pharmacol. Rev. 20, l (1968), and references cited therein. A few of those biological responses are systemic arterial blood pressure lowering in the case of PGE PGF- B and PGA as measured, for example, in anesthetized (pentobarbital sodium) pentoliniumtreated rats with indwelling aortic and right heart cannulas; pressor activity, similarly measured, for PGF a stimulation of smooth muscle as shown, for example, by tests on strips of guinea pigileum, rabbit duodenum, or gerbil colon; potentiation of other smooth muscle stimulants; antilipolytic activity as shown by antagonism of epinephrine-induced mobilization of free fatty acids or inhibition of the spontaneous release of glycerol from isolated rat fat pads; inhibition of gastric secretion in the case of PGE and PGA as shown in dogs with secretion stimulated by food or histamine infusion; activity on the central nervous system; decrease of blood platelet adhesiveness as shown by platelet-toglass adhesiveness', and inhibition of blood platelet aggregation and thrombus formation induced by various physical stimuli, e.g., arterial injury, and various biochemical stimuli, e.g., ADP, ATP, serotonin, thrombin, and collagen; and in the case of PGE and PBG stimulation of epidermal proliferation and keratinization as shown when applied in culture to embryonic chick and rat skin segments.

Optically active PGE and its esters and pharmacologically acceptable salts, are also extremely potent in causing the same biological responses as PGE Horton et al., Brit. J. of Pharm. and Chemotherapy, 21, 182 (1963); Bergstrom et al., acta physio]. science, 59, 493 (1963); Heinberg et al., J. Clinic. Investigation, 43,

7 1533 (1964); Bergstrom et al., acta physiol. science, 60, 170 1964); and Sandberg'et al., Acta Obstetrica er Gynecolojica Science, 43, 95 (1964). Optically active PGF and PGA;; which are obtained from optically active PGE also cause the same biological responses as PGF and PGA Because of these biological responses, these known prostaglandins are useful to study, prevent, control, or alleviate a wide variety of diseases and undesirable physiological conditions in birds and mammals, including humans, useful domestic animals, pets, and zoological specimens, and in laboratory animals, for example, mice, rats, rabbits, and monkeys.

For example, these compounds, and especially PGE are useful in mammals, including man, as nasal decongestants. For this purpose, the compounds are used in a dose range of about 10 ug. to about 10 mg. per ml. of a pharmacologically suitable liquid vehicle or as an aerosol spray, both for topical application. PGE is similarly useful when administered in equivalent doses.

PGE and PGA are useful in mammals, including man and certain useful animals, e.g., dogs and pigs, to reduce and controlexcessive gastric secretion, thereby reducing or avoiding gastrointestinal ulcer formation, and accelerating the healing of such ulcers already present in the gastrointestinal tract. For this purpose, the compounds are injected or infused intravenously, subcutaneously, or intramuscularly in an infusion dose range about 0.1 ug. to about 500 pg. per kg. of body weight per minute, or in a total daily dose by injection of infusion in the range about 0.1 to about mg. per kg. of body weight per day, the exact dose depending on the age, weight, and condition of the patient or animal, and on the frequency and route of administration.-

PGE and PGA are similarly useful when administered in equivalent doses.

PGE PGA PGF a and PGF B are useful whenever it is desired to inhibit platelet aggregation, to reduce the adhesive character of platelets, and to remove or prevent the formation of thrombi in mammals, including man, rabbits, and rats. For example, these compounds are useful in the treatment and prevention of myocardial infarcts, to treat and prevent post-operative thrombosis, to promote patency of vascular grafts following surgery, and to treat conditions such as atherosclerosis, arteriosclerosis, blood clotting defects due to lipemia, and other clinical conditions in which the underlying etiology is associated with lipid imbalance or hyperlipidemia. For these purposes, these compounds are administered systemically, e.g., intravenously, subcutaneously, intramuscularly, and in the form of sterile implants for prolonged action. For rapid response, especially in emergency situations, the intravenous route of administration is preferred. Doses in the range about 0.004 to about 20 mg. per kg. of body weight per day are used, the exact dose depending on the age, weight, and condition of the patient or animal, and on the frequency and route of administration. PGE PGA PGF a and PGF:; 3 are similarly useful when administered in equivalent doses.

PGE PGA PGF a and PGF are especially useful as additives to blood, blood products, blood substitutes, and other fluids which are used in artificial extracorp'oreal circulation and perfusion of isolated body portions, e.g., limbs and organs, whether attached to the original body, detached and being preserved or pre pared for transplant, or attached to a new body. During these circulations and perfusions, aggregated platelets tend to block the blood vessels and portions of the circulation apparatus. This blocking is avoided by the presence of these compounds. For this purpose, the compound is added gradually or in single or multiple portions to the circulating blood, to the blood of the donor animal, to the perfused body portion, attached or detached, to the recipient, or to two or all of those at a total steady state dose of about 0.001 to 10 mg. per liter of circulating fluid. It is especially useful to use these compounds in laboratory animals, e.g., cats, dogs, rabbits, monkeys, and rats, for these purposes in order to develop new methods and techniques for organ and limb transplants. PGE PGA PFGga and PFG B are similarly useful when administered in equivalent doses.

PGE is extremely potent in causing stimulation of smooth muscle, and is also highly active in potentiating other known smooth muscle stimulators, for example, oxytocic agents, e.g., oxytocin, and the various ergot alkaloids including derivatives and analogs thereof. Therefore PGE is useful in place of or in combination with less than usual amounts of these known smooth muscle stimulators, for example, to relieve the symptoms of paralytic ileus, to control or prevent atonic uterine bleeding after abortion or delivery, to aid in expulsion of the placenta, and during the puerperium. For these purposes, PGE is administered by intravenous infusion immediately after abortion or delivery at a dose in the range about 0.01 to about 50 pg. per kg. of body weight per minute until the desired effect is obtained. Subsequent doses are given by intravenous,'subcutaneous, or intramuscular injection or infusion during puerperium in the range 0.01 to 2 mg. per kg. of body weight per day, the exact dose depending on the age, weight, and condition of the patient or animal. PGE is similarly useful when administered in equivalent doses.

PGE PGA and PGF B are useful as hypotensive agents to reduce blood pressure in mammals, including man. For this purpose, the compounds are administered by intravenous infusion at the rate about 0.01 to about 50 ,ug. per kg. of body weight per minute or in single or multiple doses of about 25 to 500 pg. per kg. of body weight total per day. PGE PGA and PGF are similarly useful when administered in equivalent doses.

PGE PGF a and PGF B are useful in place of oxytocin to induce labor in pregnant animals, including man, cows, sheep, and pigs, at or near tenn, or in pregnant animals with intrauterine death of the fetus from about 20 weeks to term. For this purpose, the compound is infused intravenously at a dose 0.01 to 50 pg. per kg. of body weight per minute until or near the termination of the second stage of labor, i.e., expulsion of the fetus. These compounds are especially useful when the female is one or more weeks post-mature and natural labor has not'started, or 12 to 60 hours after the membranes have ruptured and natural labor has not yet started. PGE PGF a and PGF are similarly useful when administered in equivalent doses.

PGF a PGF and PGE are useful for controlling the reproductive cycle in ovulating female mammals, including humans and animals such as monkeys, rats, rabbits, dogs, cattle, and the like. For that purpose, PGF a is administered systemically at a dose level in the range 0.01 mg. to about 20 mg. per kg. of body weight of the female mammal, advantageously during a span of time starting approximately at the time 9 of ovulation and ending approximately at the time of menses or just prior to menses. PGE PGF and PGF are similarly useful when administered in equivalent doses.

As mentioned above, PGE is a potent antagonist of epinephrine-induced mobilization of free fatty acids. For this reason, this compound is useful in experimental medicine for both in vitro and in vivo studies in mammals, including man, rabbits, and rats, intended to lead to the understanding, prevention, symptom alleviation, and cure of diseases involving abnormal lipid mobilization and high free fatty acid levels, e.g., diabetes mellitus, vascular diseases, and hyperthyroidism. PGE is similarly useful when administered in equivalent doses. Y

PGE and PGB promote and accelerate the growth of epidermal cells and keratin in animals, including humans, useful domestic animals, pets, zoological specimens, and laboratory animals. For that reason, these compounds are useful to promote and accelerate healing of skin which has been damaged, for example, by burns, wounds, and abrasions, and after surgery. These compounds are also useful to promote and accelerate adherence and growth of skin autografts, especially small, deep (Davis) grafts which are intended to cover skinless areas by subsequent outward growth rather than initially, and to retard rejection of homografts. PGE and PGB are similarly useful when administered in equivalent doses. v

For these purposes, these compounds as well as the compounds of the invention are preferably administered topically at or near the site where cell growth and keratin formation is desired, advantageously as an aerosol liquid or micronized powderspray, as an isotonic aqueous solution in thecase 'of wet dressings, or as a tion, cream, or ointment in combination with the usual pharmaceutically acceptable diluents. In some instances, for example, when there is substantial fluid loss as in the case of extensive burns or skin loss due to other causes, systemic administration is advantageous, for example, by intravenous injection or infusion, separate or in combination with the usual infusions of blood, plasma, or substitutes thereof. Alternative routes of administration are subcutaneous or intramuscular near the site, oral, sublingual, buccal, rectal, or vaginal. The exact dose depends on such factors as the route of administration, and the age, weight, and condition of the subject. Especially for topical use, these prostaglandins are useful in combination with antibiotics, for example, gentamycin, neomycin, polymyxin B, bacitracin, spectinomycin, and oxytetracycline, with other antibacterials, for example, mafenide hydrochloride, sulfadiazine, furazolium chloride, and nitrofurazone, and with corticoid steroids, for example, hydrocortisone, prednisolone, methylprednisolone, and fluprednisolone, each of these being usedin the combina tion at the usual concentration suitable for its use alone.

produced by chemical reactions rather than by extrac- IXe, when CH CH=CHACOOR is attachedin alpha configuration and,in the case of formula IXe, when the ring hydroxy is also attached in alpha configuration, the sterochemistry is typical of the known optically active PGE and PGE According to this invention, preferred formula VIlle and lXe compounds are those wherein Cl-l CH=CHA---COOR and ring hydroxy are alpha, in is l andA is trimethylene, R

is hydrogen and R is hydrogen or methyl and R is ethyl. These preferred compounds exhibit superior biological response specificity and/or potency.

Certain compounds, within the scope of formulas Vllle to Xle are especially useful for one or more of the purposes stated above, because they have a substantially longer duration of activity 'than other compounds within the generic formulas, including PGE PGF r PGF PGA and PGB and because they can be administered orally, sublingually, intravaginally, buccally, or rectally, rather than by the usual intravenous, intramuscular, or subcutaneous injection or infusion as indicated above for the uses of these known prostaglandins and the other compounds encompassed by formulas Vllle to Xle. These qualities are advantageous because they facilitate maintaining uniform levels of these compounds in the body with fewer, shorter, or smaller.

doses, and make possible self-administration by the patient.

With reference to formulas Vllle to Xle, these special compounds include those wherein A'is (CH ),,Z-,, wherein b is 0, 1, 2, or 3, and Z is ethylene substituted by one or 2 fluoro, methyl, or ethyl, or by one alkyl of 3 or 4 carbon atoms. These special compounds also include those wherein R is ethyl, propyl, isopropyl, isopropyl, isobutyl, tert-butyl, 3,3-difluorobutyl, 4,4- difluorobutyl, or 4,4,4-trifluorobutyl. These special compounds also include those wherein A is (CH --Z- as above defined, and R is ethyl, propyl, isopropyl, isobutyl, tert-butyl, 3,3-difluorobutyl, 4,4- difluorobutyl, or 4,4,4-trifluorobutyl. Especially preferred among these spacial compounds are those wherein 'R and R, are both hydrogen.

In the case of Z, the divalent ethylene group, -CH- -CH is substituted" on either or both carbon atoms, i.e., alpha and/or beta to the carboxylate function. For example, Z is' CH CHF., CH-. FCH CH CF -CHFCHF, -CH- 8c Cl-l(CH CH(CH )-CH Cl-l- 2" 3)2 I C 3)2' 2' v )CH(CH and similarly for' ethyl, and for one fluoroand one methyl, one fluoro and one ethyl, and one methyl and one ethyl. Z is alternatively ethylene substituted on either carbon atoms with propyl, isopropyl, butyl, isobutyl, sec-butyl, or-tert-butyl.

Although all of the special compounds just described have the special advantages of long duration and oral, sublingual intravaginal, and rectal routes of administration, there is a still more limited group of compounds encompassed by these formulas which have these qualities in a particularly high degree. Those are the compounds wherein A is CH Z, i.e., wherein b in (CH ),,-Z is one, especially when Z is ethylene with one fluoro or methyl, with 2 fluoro or 2 methyl on the same carbon atoms, or with butyl, isobutyl, secbutyl, or tert-butyl on the carbon atoms alpha (adjacent) to the carboxylate function, the compounds wherein R2 iS C(CH3)3, -CH2CH(CH3)2, CH2CF3, --CH CHF or CH CF CH and the compounds wherein both A and R are both defined in these more limited ways.

Racemic PGE racemic PGF racemic PGF racemic PGA racemic PGB and the other compounds encompassed by formulas Vllle and Xle, are used for the purposes described above in the free acid form, in ester form, or in pharmacologically acceptable salt form. When the ester form is used, the ester is any of those within the above definition of R However, it is preferred that the ester be alkyl of one to four carbon atoms, inclusive. Of those alkyl, methyl and ethyl are especially preferred for optimum absorption of the compound by the body or experimental animal system.

Pharmacologically acceptable salts of these formula Vllle, lXe, Xe, and Xle compounds useful for the purposes described above are those with pharmacologically acceptable metal cations, ammonium, amine cations, or quaternary ammonium cations.

Especially preferred metal cations are those derived from the alkali metals, e.g., lithium, sodium, and potassium, and from the alkaline earth metals, e.g., magnesium and calcium, although cationic forms of other metals, e.g., aluminum, zinc, and iron, are within the scope of this invention.

Pharmacologically acceptable amine cations are those derived from primary, secondary, or tertiary amines. Examples of suitable amines are methylamine, dimethylamine, trimethylamine, ethylamine, dibutylamine, triisopropylamine, N-methylhexylamine, decylamine, dodecylamine, allylamine, crotylamine, cyclopentylamine, dicyclohexylamine, benzylamine, dibenzylamine, a-phenylethylamine, B-phenylethylamine, ethylenediamine, diethylenetriamine, and like aliphatic, cycloaliphatic, and araliphatic amines containing up to and including about 18 carbon atoms, as well as heterocyclic amines, e.g., piperidine, morpholine, pyrrolidine, piperazine, and lower-alkyl derivatives thereof, e.g., l-methylpiperidine, 4-ethylmorpholine, l-isopropylpyrrolidine, 2-methylpyrrolidine, 1,4- dimethylpiperazine, 2-methylpiperidine, and the like, as well as amines containing water-solubilizhng or hydrophilic groups, e.g., mono-, di-, and triethanolamine, ethyldiethanolamine, N-butylethanolamine, 2-aminol-butanol, 2amino-2-ethyll ,3-propanediol, Z-amino- 2-methyll -propanol, tris( hydroxymethyl )aminomethane, N-phenylethanolamine, N-(p-tert-amylphenyl)- diethanolamine, galactamine, N-methylglucamine, N- methylglucosamine, ephedrine, phenylephrine, epimephrine, procaine, and the like.

Examples of suitable pharmacologically acceptable quaternary ammonium cations are tetramethylammonium, tetramethylammonium, tetraethylammonium, benzyltrimethylammonium, phenyltriethylammonium, and the like.

As discussed above, the compounds of formulas Vllle to Xle are administered in various ways for various purposes; e.g., intravenously, intramuscularly, subcutane- 12 ously, orally, intravaginally, rectally, buccally, sublingually, topically, and in the form of sterile implants for prolonged action.

For intravenous injection or infusion, sterile aqueous isotonic solutions are preferred. For the purpose, it is preferred because of increased water solubility that R in the formula Vllle to Xle compound be hydrogen or a pharmacologically acceptable cation. For subcutaneous or intramuscular injection, sterile solutions or suspensions of the acid, salt, or ester form in aqueous or non-aqueous media are used. Tablets, capsules, and liquid preparations such as syrups, elixers, and simple solutions, with the usual pharmaceutical carriers are used for oral or sublingual administration. For rectal or vaginal administration, suppositories prepared as known in the art are used. For tissue implants, a sterile tablet or silicone rubber capsule or other object containing or impregnated with the substance is used.

Racemic PGE racemic F'GF a racemic PGF B racemic PGA racemic PGB and the other compounds encompassed by formulas Vllle, lXe, Xe, and Xle are produced by the reactions and procedures described hereinafter. As interrnediates there are produced the corresponding 5,6,17, l 8-dehydroprostaglandins Vllld, lXd, Xd, and Xld which in the free acid or salt forms are useful also for the purposes given above. The enantiomorphs of the Vlll, IX, X, and X1 compounds are formed either by resolution of the final product racemate or a racemic intermediate.

Racemic PGF racemic PGF and the other PGF -type compounds encompassed by formula 1X are prepared by carbonyl reduction of the corresponding PGE -type compounds encompassed by formula Vlll. For example, carbonyl reduction of racemic PGE Vllle, gives a mixture of racemic PGF lXea, racemic PGF;, 5 lXeB. The corresponding 5,6,l7,l8-dehydro PGF -type compounds, lXd, are produced in a like manner from 5,6,l7,l8-dehydro-PGE -type compounds, Vllld, and by hydrogenation of the acetylenic bonds are converted to the corresponding PGF -type compounds, lXe.

These ring carbonyl reductions are carried out by methods known in the art for ring carbonyl reductions of known prostanoic acid derivatives. See, for example, Bergstrom et al., Arkiv Kemi, 19, 563 (1963), and Acta Chem. Scand. 16, 969 1962), and British Specification No. 1,097,533. Any reducing agent is used which does not react with carbon-carbon double bonds or ester groups. Preferred reagents are lithium (tri-tert-butoxy) aluminum hydride and the metal borohydrides, especially sodium, potassium and zinc borohydrides. The mixtures of alpha and beta hydroxy reduction products are separated into the individual alpha and beta isomers by methods known in the art for the separation of analogous pairs of known isomeric prostanoic acid derivatives. See, for example, Bergstrom et al., cited above, Granstrom et al., J. Biol. Chem. 240, 457 (1965), and Green et al., J. Lipid Research, 5, 117 (1964). Especially preferred as separation methods are partition chromatographic procedures, both normal and reversed phase, preparative thin layer chromatography, and countercurrent distribution procedures. They can be applied either before or after the hydrogenation of the acetylenic bonds.

Racemic PGA and the other PGA -type compounds encompassed by formula X are prepared by acidic dehydration of the corresponding PGE -type compounds encompassed by formula Vlll. For example, acidic de- 13 hydration of racemic PGE Vllle, gives racemic PGA Xe. The corresponding 5,6,l7,18-dehydro-PGA -type compounds Xd, are produced in a like manner from 5,6,17,l8-dehydro-PGE -type compounds, Vllld, and by hydrogenation of the acetylenic bonds are converted to PGA -type compounds, Xe.

These acidic dehydrations are carried out by methods known in the art for acidic dehydrations of known prostanoic acid derivatives. See, for example, Pike et al., Proc. Nobel Symposium 11, Stockholm (1966), Interscience Publishers, New York, p. 161 1967); and British Specification No. 1,097,533. Alkanoic acids of 2 to 6 carbon atoms, inclusive, especially acetic acid, are preferred acids for this acidic dehydration. They can be applied either before or after the hydrogenation of the acetylenic bonds.

Racemic PGB and the other compounds encompassed by formula Xle are prepared by basic dehydration of the corresponding PGE -type compounds encompassed by formula Vllle or by contacting the corresponding PGA -type compounds encompassed by formula Xe with base.- Forelx-ample, both racemic PGE Vllle, and racernic PGA Xe, give racemic PGB Xle, on treatment with base. Presumably the base first causes dehydration of the PGE to PGA and then causes the ring double bondo PG to migrate to a new position. The correspond g- ,6 ,17,l8dehydro- PGB -type compounds, Xld, are produced in a like manner from 5,6,l7,18-dehydro-PGE Vllla', or 5,6,l7,l8-dehydroPGA -type compounds, Xd, and by 14 hydrogenation of the acetylenic bonds are converted to PGB -type compounds, Xld.

These basic dehydrations and double bond migratiions are carried out by methods known in the art for similar reactions of known prostanoic acid derivatives. See, for example, Bergstrom et al., J. Biol. Chem. 238, 3555 (1963). The base is any whose aqueous solution has pH greater than 10. Preferred bases are the alkali metal hydroxides. A mixture of water and sufficient of a water-miscible alkanol to give a homogeneous reaction mixture is suitable as a reaction medium. The PGE -type or PGA -type compound is maintained in such a reaction medium until no further PGB -type compound is formed, as shown by the characteristic ultraviolet light absorption for the PGB -type compound. They can be applied either before or after the hydrogenation of the acetylenic bonds.

These various transformations of the PGE -type compounds of formulas Vllle to the PGF -type, lXe, PGA type, Xe, and PGB -type, Xle, compounds are shown in Chart A, wherein R R R R A, and are as defined above. The same transformation can be applied to the 5,6,l7,l8-dehydro-PGE -type compounds, Vllld, as shown in Chart A-l. If desired, the 5,6,17,18-dehydro- PGA -type compounds, Xd, can be converted to PGA type compounds, Xe, by hydrogenation by the procedures of step 8 and 8a, infra.

Racemic PGE and the other PGE -type compounds encompassed by formula Vlll are prepared by the multi-step processes outline in Charts B, C, and D.

CHART A-continued ACOOR CHART A-l CH- .--C 8 C-A-COOR base 0 base CH -C i C-ACOOR Vllld XII Stay

CHART B-continued CL CL XXV OH OH XXIV L alkanesulfonyl group. e.gv. mesyI CHART c CHART C-continued Br-A-CH,OH XXI Br-A-CH,O- xx CH O S0-CH,--C i C-AYCHZO XVIII CL CL XXV Step 7% Step 7b The bicylic compound of formula Xll in Chart B is the initial reactant in these multi-step processes. It exists in two isomeric forms, exo and endo with respect to the attachment of the CR O moiety. it also exists in two isomeric forms with respect to the attachment of the tetrahydropyranyloxy group making in all four isomeric fonns. Each of those isomers separately or mixtures thereof are used as reactants according to this invention to produce substantially the same final PGE type or 5,6,17,l8-dehydro-PGE -type product mixture.

In Belgian Pat. No. 702,477; reprinted in Farmdoc Complete Specifications, Book 714, No. 30,905, page 313, Mar. 12, 1968, the reaction sequence leading to exo form of compound Xll is as follows: The hydroxy of 3-cycl0pentenol is protected, for example, with a tetrahydroyranyl group. Then a diazoacetic acid ester is wherein R is as defined above.

In the first step of the process (Chart B), the aldehyde group or keto group is transformed by the Wittig reaction to a moiety of the formula -CR,=CR C,,H-

21 -C E CR which is in exo configuration relative to the bicyclo ring structure, and is the same as shown in formula Xlll. In step 2, the protective group is removed to regenerate the 3-hydroxy (XIV) which is then oxidized in step 3, for example, by the Jones reagent, to give the exo compound XV.

Separation of the cis-exo and trans-exo isomers of XV can be effected by the procedures described in said Belgian patent. However, as mentioned above, that separation is usually not necessary since the cis-trans mixture is useful as a reactant in the next process step.

The process described in said Belgian Pat. No. 702,477 for producing the exo form of bicyclic compound Xll uses as an intermediate, the exo form of a bicyclo[3. I .0]-hexane substituted at 3 with a protected hydroxy, e.g., tetrahydropyranyloxy and at 6 with an esterified carboxyl. When the corresponding endo compound is substituted for that exo intermediate, the Belgian patent process leads to the endo form of bicyclic compound XII. That endo intermediate used in the Belgian patent process has the formula:

COOCHa XXVII Compound XXVll is prepared by reacting endo-bicyclo-[3.I.0]hex-2-ene-6-carboxylic acid methyl ester with diborane in a mixture of tetrahydrofuran and di-' ethyl ether, a reaction generally known in the art, to give endobicyclo[ 3. l .0]hexan-3-ol-6-carboxylic acid methyl ester which is then reacted with dihydropyran in the presence of a catalytic amount of POCI to give the desired compound. This is then used as described in said Belgian patent to produce the endo form of bicyclic compound Xll.

Using this endo form of bicyclic compound Xll as the starting material, steps 2 and 3 produce mixtures of endocis and endo-trans. These canbe separated as described for the separation of exo-cis and exo-trans XV, but this separation is usually not necessary since, as mentioned above, the cis-trans mixture is useful as a reactant in the next process step.

In the Wittig reaction, (Step I), the other starting compound is an organic chloride or bromide, or iodide of the formula HalCI-IR C,,H ,,C 5 CR XXVIII This can be prepared from the corresponding alcohol HO-CHR C,,H ,,-C E C-R XXIX 0=CHC,,H.,,, C E c R xxx with the appropriate Grignard reagent, BrMgR These acetylenic aldehydes can be made by oxidizing the corresponding alcohol, for example, those listed above, with a Jones reagent, Collins reagent, a Moffatt oxidation or the like. The aldehyde is then reacted with BrMgR to prepare acetylenic alcohols of formula XXIX. Compounds thus obtainable include 4-hexyn-2- ol, 4-heptyn-2-ol, 5-heptyn-2-ol, 3-methyI-4-hexyn-2- ol, 3,4-dimethyl-S-hexyn-Z-ol, 7-nonyn-2-ol, 7-decyn- 2-ol, 5-dodecyn-2-ol, 7-tridecyn-2-ol, 5-heptyn-3-ol, 5-octyn-3-ol, 6-octyn-3-ol, 8-undecyn-3-ol, 6-tridecyn 3-ol, 8-tetradecyn-3-ol, and the like. Still other alkyn- I ols according to formula XXIX (R Hydrogen) can be made by condensing an omega-alkyl-I-ol of the formula HOCH2C,,H2,,.C E CH xxx] with an alkyl halide, HalR using lithium and ammonia as the condensing agent; still others by condensing a protected halohydrin of the formula with a l-alkyn, HC E CR Again lithium and ammonia can be used as the condensing agent.

The protective tetrahydropyranyl group XXXII can then be removed by acid hydrolysis to form an acetylenic alcohol of formula XXIX. The latter process is particularly useful where R is a halo substituted alkyl. The I-alkyn, HC E CR can be made by condensing acetylene with or sodium acetylide with an alkyl halide, R Hal where R is as given above.

The transformation of bicyclo-ketone-olefin XXlll to glycol XXIV (Step 5, Chart B) is carried out by reacting olefin XXIII with a hydroxylation reagent. Hydroxylation reagents and procedures for this purpose are known in the art. See, for example, Gunstone, Advances in Organic Chemistry; Vol. I, pp. 103-147, Interscience Publishers, New York, NY. (1960). Various isomeric glycols are obtained depending on whether olefin XXIII is cis or trans and endo or exo, and on whether a cis or a trans hydroxylation reagent is used. Thus endocis olefin XXIII gives a mixture of two isomeric erythro glycols of formula XXIV with a cis hydroxylation agent, e.g., potassium permanganate. The endo-cis olefins and the endo-trans olefins XXIII give similar mixtures of two threo isomers with cis and trans hydroxylation reagents, respectively. These various glycol mixtures are separated into individual isomers by silica gel chromatography. However, this separation is usually not necessary, since each isomeric erythro glycol and each isomeric threo glycol is useful as an intermediate according to this invention and the processes outlined in Charts B, C, and D to produce final products of formulas VIIIe and Xe, and then, according to Chart A, to produce the other final products of this invention. Thus the various isomeric glycol mixtures encompassed by 23 formula XXIV produced from the various isomeric olefins encompassed by formula XXIII are all useful for these same purposes.

In step 4 the other starting material is a haloalkynoic ester of the formula HalCH C E C-A-COOR, wherein'I-Ial is chlorine, bromine, or iodine. In effecting this step any of the alkylation procedures known in the art to be useful for alkylating cyclic ketones with alkyl halides, especially haloalkynoic esters, can be used for the transformation of XV to XXIII. See, for example, the above mentioned Belgian Pat. No. 702,477 for procedures useful here and used there to carry out similar alkylations.

For this alkylation, it is preferred that Hal be bromo, or iodo. Any of the usual alkylation bases, e.g., alkali metal alkoxides, alkali metal amides, and alkali metal hydrides, are useful for this alkylation. Alkali metal alkoxides are preferred, especially tert-alkoxides. Sodium and potasssium are preferred alkali metals. Especially preferred is potassium tert-butoxide. Preferred diluents for this alkylation are tetrahydrofuran and 1,2- dimethoxyethane. Otherwise, procedures for producing and isolating the desired formula XXIII compound are within the skill of the art.

This alkylation procedure produces a mixture of alpha and beta alkylation products, i.e., a mixture of formula XXIII products wherein part has the CH C CACOOR moiety attached in alpha configuration and wherein part has that moiety attached in beta configuration. When about one equivalent of base per equivalent of formula XV ketone is used, the alpha configuration usually predominates. Use of an excess of base and longer reaction times usually result in production of larger amounts of beta products. These alphabeta isomer mixtures are separated at this stage or at any subsequent stage in the multi-step processes shown in Charts B and D. Silica gel chromatography is preferred for this separation.

An alternative alkylation procedure is shown in steps 4a, 4b, and 4c. The alkylating agent XVII is reacted with the bicyclo-ketone-olefin XV by the alkylation procedure described above for step 4.

The alkylating agent of formula XVII is prepared by the series of reactions shown in Chart C. The initial reactants, Br --ACI-I OH, are omega bromoalcohols which are known in the art or can be prepared by methods known in the art. For example, when A in the final product is to be trimethylene as it is in racemic PGE the necessary 4-bromobutanol is prepared by reacting tetrahydrofuran with hydrogen bromide.

To illustrate the availability of the other bromoglycols of formula XXI (Chart C), consider the abovedescribed special compounds of formula VIIIe, wherein A is -(CH ),,Z-, wherein b is zero, one, 2, or 3, and Z is ethylene substituted by one or 2-fluoro, methyl, or ethyl, or by one alkyl of 3 or 4 carbon atoms. These omega-bromoalcohols, Br(CH ,,ZCI-I OI-l, are prepared by starting with the appropriate succinic acid, HOOCZCOOH, all of which are known or easily accessible by known methods. These succinic acids are transformed to the corresponding anhydrides by known procedures. Each anhydride is then reacted with an alkanol, for example, methanol, to give the corresponding succinic acid half ester, e.g., HOOC-Z- COOCH When Z is unsymmetrical, e.g., substituted with one fluoro, a mixture of isomeric half esters is ob- 24 tained, HOOCZCOOCH and CH OOCZ- COOH, which is separated to give the desired isomer.

When it is desired that b is Br(CH )bZCH OH be zero, the succinic acid half ester is subjected to the I-Iunsdiecker reaction, thereby producing Br-Z-- COOCI-I which is reduced by lithium aluminum hydride to BrZCI-I OH. When b is to be one, the carboxyl group of the succinic acid half ester is changed to acid chloride with thionyl chloride, to aldehyde by the Rosenmund reduction, to alcohol with sodium borohydride, and to CI-I Br with PBr giving BRCH- Z-COOCH which is then reduced to BrCH- ,ZCH Ol-l with lithium aluminum hydride. When b is to be 2 or 3, the succinic acid half ester is subjected once or twice to the Arndt-Eistert reaction to produce HOOC-CI-I Z-COOCl-I or I-IOCCCI-I C- H -Z-COOCH which is then subjected to the same series of reactions given above to give Br-CH C- H ZCH OH or BrCH- CH CH ZCI-I OH.

Referring again to Chart C, the several process steps, XXI to XX, XX to XIX, XIX to XVIII, and XVIII to XVII are exemplified in Belgian patent application Ser. No. 747,348, Sept. 14, I970, in the case wherein A is trimethylene. Those procedures are used when A is other than trimethylene and within the scope of A as defined above.

The transformation of alkylation product XVI to primary alcohol XXII (Chart B) is carried out by acid catalyzed hydrolysis of the tetrahydropyranyl ether XVI. Such hydrolysis of tetrahydropyranyl ethers is well known to those skilled in the art. Oxalic acid is especially preferred for this acid hydrolysis of XVI to XXII.

The oxidation of primary alcohol XXII to carboxylic acid XXIII (Chart B, R H) is carried out by oxidizing XXII with any oxidizing agent which will not also attack theacetylenic linkage in XXII. An especially useful reagent for this purpose is the Jones reagent, i.e., acidic chromic acid. See J. Chem. Soc. 39 (1946). Acetone is a suitable diluent for this purpose, and a slight excess of oxidant and temperatures at least as low as about 0 C., preferably about l0 to about 20 C. should be used. The oxidation proceeds rapidly and is usually complete in about 5 to about 30 minutes. Excess oxidant is destroyed, for example, by addition of a lower alkanol, advantageously isopropyl alcohol, and the aldehyde is isolated by conventional methods, for example, by extraction with a suitable solvent, e.g., diethyl ether. Other oxidizing agents can also be used. Examples are mixtures of chromium trioxide and pyridine or mixtures of dicyclohexylcarbodiimide and dimethyl sulfoxide. See, for example, J. Am. Chem. Soc. 87, 5661 (1965).

The acid thus formed (compound XXIII, R H) can then be esterified by procedures already known in the art for transforming carboxylic acids to esters. For example, a diazohydrocarbon, e.g., diazometharie, advantageously in diethyl ether solution, is reacted with the acidto produce the ester, e.g., the methyl ester, by known procedures. When R is ethyl substituted with 3-chloro, 2 or 3 bromo, or I, 2, or 3 iodo, the acid is reacted with the appropriate haloethanol, e.g., 6,5, B-trichloroethanol, in the presence of a carbodiimide, e.g., dicyclohexylcarbodiimide, and a base, e.g., pyridine. This mixture, advantageously with an inert diluent, e. g., dichloromethane, usually produces the desired haloethyl ester within several hours at about 25 C. The other esters within the scope of R are prepared by procedures known to the art.

In step 6 the vicinal hydroxy groups of the glycol XXIV are modified by replacingthe hydrogens with an alkanesulfonyl leaving-group, L, for example mesyl, containing up to and including 5 carbon atoms. Thus, the bisalkanesulfonic acid esters XXV (Chart B) are prepared by reacting glycol XXIV with an alkylsulfonyl chloride or bromide, or with an alkanesulfonic acid anhydride. Alkylsulfonyl'v chlorides are preferred for this reaction. The reaction is carried out in the presence of a base to neutralize the by-;product acid. Especially suitable bases are tertiary amines, e.g., dimethylaniline or pyridine. It is usually suffici-ent merely to mix the two reactants and the base, and maintain the mixture in the range to 25 C. for several hours. The formula XXV bis-alkanesulfonic acid esters are then isolated by procedures known to the art.

The transformation in Chart D, Step 7a, of the modified glycol XXV to Vllld is carried out by reacting XXV with water in the range about 0 to about 60 C. The resulting product is racemic 5,6,17,18-dehydro- PGE or an analog thereof. In making racemic 5,6,l7,I8-dehydro-PGE usually 25 C. is a suitable reaction temperature, the reaction then proceeding to completion in about to 10 hours. It is advantageous to have a homogenous reaction mixture. This is accomplished by adding sufficient of a water-solubleorganic diluent which does not enter into the reaction. Acetone is a suitable diluent. The desired product isisolated by evaporation of excess water and diluent if one is used. The residue contains a mixture of formula VIIId isomers which differ in the configuration of the side chain hydroxy, that being either R or S. These are separated from by-products and from each other by silica gel chromatography..A usual by-product is the mono-sulfonic acid ester of formula XXVI (Chartv D). This mono-sulfonic acid ester is esterified to the formula XXV bis-sulfonic acid ester int the same manner deof carbonic, acid, especially alkali metal bicarbonates,

scribed above for the transformation of glycol XXIV to, I

bis-ester XXV, and thus is recycled in step 7a.-

For the transformation of bis-esters XXV to the formula VIIId products, it is preferred to use the bis-mesyl esters, i.e., compounds XXV wherein-L is mesyl.

In step 8a the acetylenic linkages are hydrogenated to olefinic linkages. A suitable method is to hydrogenate over a Lindlar catalyst-in the presence of quinoline. The Lindlarcatalyst is 5% palladium-on-barium sulfate. Methanol or like inert solvent or diluent is used and the pressure is low, advantageously slightly above atmospheric and ordinarily not above about two atmospheres. The resulting products can be isolated by silica gel chromatography. If thestartingmatetial contains both the R and S epimer s, the product VIIIe will also contain the and Sepimers. These also can be separated by silica gelchromatography. As shown on Chart D, the hydrogenation of VIIId (or Xd) leads to PG;,-- type-compounds depending on whether the acetylenic bonds of VIIId (or Xd) are reducedzto cisCH=ClI+-. The above described hydrogenation gives this type of reduction of theacetylenic bOIIdSL v The transformation 10f the protected: glycols XXV (Step 71;) tof5 ,6, I Z, I 8-dehydro-PGA- etype compounds (Xd) is carried out by heating the formula XXV bisester in the range 4O. to 100 C; with a combinationof water, a base characterized by its waterisolution having apH 8 to 12, and sufficient inert water-solubIe'organic diluent. to form a basic and substantially homogenous reaction mixture. A reaction time of one to 10 hours is usually used. Preferred basesare the water-soluble salts e.g., sodium bicarbonate. A suitable diluentis acetone. The products are isolated and separated as described above for step;7a and hydrogenated as in step 8a. The same mono-sulfonic acid esters XXVI observed as byproducts in step. 7a are also observed in step 7b. Also, as in step 71;. the. bis-m esyl esters XXV are preferred. Also as in steps 7a and 8a, during production of Xd and Xe, alpha XXV gives-alpha Xd and alpha Xe, beta XXV gives beta Xd and beta, Xe, and in each case, alphaand beta Xd and Xe, a mixtureof R and S isomers is obtained. These R and S isomer mixtures are separatedby silica gel chromatography. 7

The configuration of the --CI-I C- E CA-COOR moiety does not change during these transformations of Charts B and D. Also the configuration does not change in hydrogenation. Therefore, when the CI-I C E C-A-COOR, is attached initially in alpha configuration racemic 5,6,17,18-dehydrO-PGE -type, Vllld, PGE -type, VIIIe, 5,6,17,18- dehydro-PGA -type, Xd, and PGA -type, Xe, compounds are obtained, and when the moiety is attached in beta configuration, the 8-isoforms are obtained.

Resolution of the final product racemates or the racemic intermediates are carried -out by procedures known in the art. For example, when a final compound of formula VIIIe, IXe, Xe, or XIe is a free acid, the dl form (racemate) thereof is resolvedinto the d and 1 forms (the natural and unnatural configurations) by reacting said free acid by known general procedures with an optically active base, e.g., brucine or strychnine, to give a mixture of two diastereoisomers which are separated by known general procedures, e.g., fractional crystallization, to give the separate diastereoisomeric salts. The optically active acid of formula VIII to XI is then obtained by treatment of the salt with an acid by known general procedures. Alternatively, the free acid form of the intermediate dehydro compounds VIIId, IXd, Xd, or Xld is resolved into separate d and 1 forms and then esterified and transformed further to the corresponding optically active form of the final product VIIIe to XIe as described above. I

Alternatively, glycol reactant XXIV, in exo orendo form, is transformed to a ketal with, an optically active 1,2-glycol, e.g., D-()-2,3-butanediol, by reaction of said 1,2-glycol with the formula XXIV compound in the presence of a strong acid, e.g., p toluenesulfonic acid. The resulting ketal is a mixturev of diastereoisomers which is sepatated into the d and l diastereoisomers, each of which is then hydrolyzed with an acid, e.g., oxalic acid, to the original keto compound, now in optically active form. These reactions involving optically active glycols for resolution purposes are generally known in the art. See, for example, Chem. Ind. 1664 (1961) and J. Am. Chem. Soc. 84, 2938 (I962). Dithiols may be used instead of glycols.

The novel PGE PGF PGA and PGB -type compounds of formula VIIIe to Xle wherein R is alkyl of one to 4 carbon atoms, inclusive, preferably methyl or ethyl, are preferred over the corresponding PGE PGF PGA and PQBfl-ype compounds in which R is hydrogen for the above-described pharmacological purposes. For convenience the compounds of the invention where R, is alkyl willbe referred to as l5-alkyl analogs even though the number actually will be greater or less than 15 depending on whether the number of methylene groups in A is greater or less than three.

27 I These l-alkyl prostaglandin analogs are surprisingly and unexpectedly more useful than the corresponding l5-hydrogen compounds for the reason that they are substantially more specific with regard to potency in causing prostaglandin-like biological responses, and

have a substantially longer duration of biological activ-' ity. For that reason, fewer and smaller'doses of these l5-alkyl prostaglandin analogs are needed to attain the desired pharmacological results.

Although the above-mentioned l5-alkyl compounds are produced by the methods outlined above in Charts A-D, the preferred methods are set forth in Charts E and F as follows.

CHART E 28 CHART F-continued PGE-type acids and alkyl esters to the corresponding S PGE-type acids and alkyl esters by oxidation. For this purpose, an oxidizing agent is used which selectively oxidizes secondary hydroxy groups to carbonyl groups in the presence of carbon-carbon double bonds. Formulav lXa in Chart Eincludes optically active compounds as shown and racemic compounds of that formula and the mirror images thereof, and also the 15- epimers of both of those, i.e., wherein the configuration at C 15 is R rather than S as shown. Also in Chart E, A, R,, R and R are as defined above, R is alkyl of one to 4 carbon atoms, and both Qs are ethynylene or cisethylene.

For the transformations of Chart E, the B-hydroxy isomersof reactant lXa are suitable starting materials when the carboxyl side chain is alpha, although the corresponding a-hydroxy isomers are also useful for this purpose.

Oxidation reagents useful for the transformation set forth in Chart E are known to the art. An especially useful reagent for this purpose is the Jones reagent, i.e., acidified chromic acid. See J. Chem. Soc. 39 (1946). Acetone is a suitable diluent for this purpose, and a slight excess beyond the amount necessary to oxidize one of the secondary hydroxy groups of the formula lXa reactant is used. Reaction temperatures at least as low as about 0 C. should be used. Preferred reaction temperatures are in the range 10 to 50 C. The oxidation proceeds rapidly and is'usually complete in about 5 to 20 minutes. The excess oxidant is destroyed,

' ethyl,

for example by addition of a lower alkanol, advantageously, isopropyl alcohol, and the formula Vllla PGE- type product is isolated by conventional methods.

Examples of other oxidation reagents useful for the Chart E transformations are silver carbonate on diatomite [Chem. Commun. 1 102 (1969)], mixtures of chromium trioxide and pyridine [Tetrahedron Letters 3363 (1968, J. Am Chem. Soc. 75, 422 (1953), and Tetrahedron, 18, 1351 (1962)], mixtures of sulfur trioxide in pyridine and dimethyl sulfoxide [J. Am. Chem. Soc. 89, 5505 (1967)], and mixtures of dicyclohexylcarbodiimide and dimethyl sulfoxide [J. Am. Chem. Soc. 87, 5661 (1965)].

The novel 15-alkyl 'PGF and PGF -type acids and esters of formula IXa are preferably prepared from the corresponding l-hydrogen compounds by the sequence of transformations shown in Chart F, wherein formulas IX, XXXVII, XXXVlIl, lXa(S), and lXa(R) include optically active compounds as shown and racemic compounds of those formulas and the mirror images thereof. Also in Chart F, R is alkyl of one to 4 carbon atoms, inclusive, and A, R R R are as heretofore defined and Q is ethynylene or cisethylene. Also in Chart F, G is alkyl of one to 4 carbon atoms, inclusive, aralkyl of 7 to 12 carbon atoms, inclusive, phenyl, or phenyl substituted with one or 2 fluoro, chloro, or alkyl of one to 4 carbon atoms, inclusive, and R is alkyl or silyl of the formula Si(G,) wherein G is as defined above. The various GS of a Si(G) moiety are alike or different. For example, a Si(G) 3 can be trimethylsilyl, dimethylphenylsilyl, or methylphenylbenzylsilyl. Examples of alkyl of one to 4 carbon atoms, inclusive, are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, and tert butyl. Examples of aralkyl of 7 to 12 carbon atoms, inclusive, are benzyl, phena-phenylethyl, 3-phenylpropyl, a-naphthylmethyl, and Z-(B-naphthyD-ethyl. Examples of phenyl substituted with one or 2 fluoro, chloro, or alkyl of one to 4 carbon atoms, inclusive, are p-chlorophenyl, mfluorophenyl, o-tolyl, 2,4-dichlorophenyl, p-tert-butylphenyl, 4-chloro-2-methylphenyl, and 2,4-dichloro-3- methylphenyl.

In Chart F the final PGF and PGF -type products are those encompassed by formulas lXa (S) and IXa(R), respectively, where both Qs are cisethylene.

The heretofore-described acids and esters of formula IX are transformed to the corresponding intermediate 15-oxo acids and esters of formula XXXll, by oxidation with reagents such as 2,3-dichloro-5,6-dicyano-1,4- benzoquinone, activated manganese dioxide, or nickel peroxide (see Fieser et al., Reagents for Organic Synthesis, John Wiley & Sons, lnc., New York, N.Y., pp. 215, 637, and 731). Alternatively, these oxidations are carried out by oxygenation in the presence of the 15- hydroxyprostaglandin dehydrogenase of swine lung [see Arkiv fc'ir Kemi 25, 293 (1966)]. These reagents are used according to procedures known in the art. See, for example, J. Biol. Chem. 239, 4097 (1964).

The novel 5,6,l7,18-dehydro-PGF -type compounds of formula IXa are obtained by the borohydride reduction of the corresponding 5,6,l7,l8-dehydro-PGE type compounds of formula Vllla. Here again the numbering is merely typical and will vary according to the values of A and n.

Referring again to Chart F, the intermediate com-' pounds of formula XXXVll are transformed to silyl derivatives of formula XXXVlIl by procedures known in the art. See, for example, Pierce, Silylation of Organic compounds, Pierce Chemical Co., Rockford, Ill. (1968). Both hydroxy groups of the formula XXXVll reactants are thereby transformed to OSi-(G) moieties wherein G is as defined above, and sufficient of the silylating agent is used for that purpose according to known procedures. When R, is the formula XXXVll intermediate is hydrogen, the COOH moiety thereby defined is simultaneously transfonned to COOSi(G) additional silylating agent being used for this purpose. This latter transformation is aided by excess silylating agent and prolonged treatment. When R in formula XXXVll is alkyl, then R in formula XXXVlIl will also be alkyl. The necessary silylating agents for these transformations are known in the art or are prepared by methods known in the art. See, for example, Post, Silicones and Other Organic Silicon Compounds," Reinhold Publishing Corp., New York, N. Y. (1949).

Referring again to Chart F the intermediate silyl compounds of the formula XXXVlIl are transformed to the final compounds of formulas lXa(S) and lXa(R) by first reacting the silyl compound with a Grignard reagent of the formula R MgHal wherein R is as defined above, and Hal is chloro, bromo, or iodo. For this purpose, it is preferred that Hal be bromo. This reaction is carried out by the usual procedure for Grignard reactions, using diethyl ether as a reaction solvent and saturated aqueous ammonium chloride solution to hydrolyze the Grignard complex. The resulting disilyl or trisilyl tertiary alcohol is then hydrolyzed with water to remove the silyl groups. For this purpose, it is advantageous to use a mixture of water and sufficient of a water-miscible solvent, e.g., ethanol to give a homogenous reaction mixture. The hydrolysis is usually complete in 2 to 6 hours at 25 C., and is preferably carried out in an atmosphere of an inert gas, e.g., nitrogen or argon. 4

The mixture of 15-5 and l5-R isomers obtained by this Grignard reaction and hydrolysis is separated by procedures known in the art for separating mixtures of prostanoic acid derivatives, for example, by chromatography on neutral silica gel. In some instances, the lower alkyl esters, especially the methyl esters of a pair of 15-S and l5-R isomers are more readily separated by silica gel chromatography than are the corresponding acids. In those cases, it is advantageous to esterify the mixture of acids, separate the two esters, and then, if desired, saponify the esters by procedures known in the art and described herein.

The novel 15-alkylPGA-type acids and esters of formula Xa are prepared from the 15-alkyl PGE compounds, Vllla, heretofore described, by dehydration as shown in Chart G. For this purpose, a dehydrating agent is used which removes the hydroxy group from the alicyclic ring in the presence of a hydroxy group on a tertiary carbon atoms. Formula Vllla includes optically active compounds as shown and racemic compounds of that formula and the mirror images thereof, and also the IS-epimers of both of those, i.e., wherein the configuration at C15 is R or S and that of the carboxyl side chain is a or ,8.

Dehydration agents useful for the transformation to PGA -type compounds set forth in Chart G are known in the art. Any of the known substantially neutral dehydrating agents is used for these reactions. See Fieser et al., Reagents for Organic Syntheses, John Wiley & Sons, Inc., New York, 1967. Preferred dehydrating agents are mixtures of at least an equivalent amount of a carbodiimide and a catalytic amount of a copper (II) salt. Especially preferred are mixtures of at least an equivalent amount of dicyclohexycarbodiimide and a catalytic amount of copper (ll) chloride. An equivalent amount of a carbodiimide means one mole of the carbodiimide for each mole of the Formula-Vllla reactant. To ensure completeness of the reaction, it is advantageous to use an excess of the carbodiimide, i.e., 1.5 to or even more equivalents of the carbodiimide.

The dehydration is advantageously carried out in the presence of an inert organic diluent which gives a homogeneous reaction mixture with respect to the Formula-Vllla reactant and the carbodiimide. Diethyl ether is a suitable diluent.

it is advantageous to carry out the dehydration in an atmosphere of an inert gas, e.g., nitrogen, helium, or argon.

' The time required for the dehydration will depend in part on the reaction temperature. With the reaction temperature in the range to C., the dehydration usually takes place in about 40 to 60 hours.

The Formula-Xa product is isolated by methods known in the art, e.g., filtration of the reaction mixture and evaporation of the filtrate. The product is then purifled by methods known in the art, advantageously by chromatography on silica gel.

The conversion of Formula-Vllla and Formula-Xa compounds to Formula Xla compounds is effected with base as described above in connection with Charts A and A-l.

The formula VIII and X compounds produced according to the processes outlined in Charts B, C, and D and discussed above are all carboxylic acid esters, wherein R is not hydrogen. Moreover, when these compounds are used to produce compounds of formulas IX and XI according to the processes outlined in Chart A and discussed above. corresponding R esters are likely to be produced, especially in the case of the PGF;, compounds of formulas IX. For some of the uses described above, it is preferred that these formula VIII 5 to Xl compounds be in free acid form, or in salt form which requires the free acid as a starting material. It is also sometimes desirable to have the free acid or salt forms of the acetylenic compounds of the 5,6,17,18- dehydro-PGE -type (Vlla') and the 5,6,17,18-dehydro- PGA -type (Xd) compounds, as well as the 5,6,17,18- dehydro-PGF -type (lXd) and 5,6,17,18-dehydro- PGB -type (Xld) compounds and which are derivable therefrom by the processes outlined in Chart A-l, because these free acids and salt forms have properties like those of the corresponding hydrogenated (olefinic) compounds and are useful for the same purposes detailed above.

The formula lXe, Xle, IXd, and Xld R -esters are easily hydrolyzed or saponified by the usual known procedures, especially when R is alkyl of one to 4 carbon atoms, inclusive. Therefore it is preferred when the free acid form of compounds IXe, Xie, IXd, and Xla' is desired, that R by such alkyl, especially methyl or ethyl.

On the other hand, the formula Vllle, Xe, Wild, and Xd products are difficult to hydrolyze or saponify without unwanted structural changes in the desired acids. There are two other procedures useful to make the free acid form of formula Ville, Xe, Wild, and Xd products.

One of those procedures is applicable mainly in preparing the free acids from the corresponding alkyl esters wherein the alkyl group contains one to 8 carbon atoms, inclusive. That procedure comprises subjecting the alkyl ester corresponding to formula VllIe, Xe, VI- lid, or Xd to the acylase enzyme system of a microorganism species of Subphylum 2 of Phylum III, and thereafter isolating the acid. Especially preferred for this purpose are species of the orders Mucorales, Hypocreales, Moniliales, and Actinomycetales. Also especially preferred for this purpose are the species of the families Mucoraceae, Cunninghamellaceae, Nectreaceae, Moniliaceae, Dematiaceae, Tuberculariaceae, Actinomycetaceae, and Streptomycetaceae. Also especially preferred for this purpose are species of the genera Absidia, Circinella, Gongronella, Rhizopus, Cunninghamella, Calonectria, Aspergillus, Penicillium, Sporotrichum, Cladosporium, Fusarium, Nocardia, and Streptomyces.

Examples of microorganisms falling within the scope of those preferred orders, families, and genera are listed in US. Pat. No. 3,290,226 and details of the process are disclosed in German Offenlegunsschift No. 1,937,678, reprinted in Farmdoc Complete Specifications, Book No. 13, No. 6863R, Week R5, Mar. 18, 1970.

This enzymatic ester hydrolysis is carried out by shaking the formula Vllle, Xe, Vllld, or Xd alkyl ester in aqueous suspension with the enzyme contained in a culture of one of the above-mentioned microorganism species until the ester is hydrolyzed. A reaction temperature in the range 20 to 30 C. is usually satisfactory. A reaction time of one to 20 hours is usually sufficient to obtain the desired hydrolysis. Exclusion of air from the reaction mixture, for example, with argon or nitrogen is usually desirable.

The enzyme is obtained by harvest of cellsfrom the culture, followed by washing and resuspension of the cells in water, and cell disintegration, forexample, by stirring with glass beads or by sonic or ultrasonic vibrations. The entire aqueous disintegration mixture is used as a source of the enzyme. Alternatively and preferably, however, the cellular debris is removed by centrifugation or filtration, and the aqueous supernatant or filtrate is used.

In some cases, it is advantageous to grow the microorganism culture in the presence of an alkyl ester of an aliphatic acid, said acid containing 10 to 20 carbon atoms, inclusive, and said alkyl containing one to 8 carbon atoms, inclusive, or to add such ah ester to the culture and maintain the culture without additional growth for one to '24' hours before cell harvest. Thereby, the enzyme produced is sometimes made more effective in transforming the formula Vllle, XXe, Vllld, or Xd ester'to the'free acid. An example of a useful alkyl ester for this purpose is methyl oleate.

Although, as mentioned above, most of the R esters encompassed by formulas Vllle, Xe, Vllld, and Xd are not easily hydrolyzed or saponified to the corresponding free acids, certain of those esters are transformed to free acids by another method. Those esters are the haloethyl esters wherein R is Cl-l CCl They are transformed to free acids by treatment with zinc metal and an alkanoic' acid of 2 to 6 carbon atoms, preferably acetic acid. Zinc dust is preferred as the physical form of the zinc. Mixing the halo ethyl ester with the zinc dust at about 25 C. for several hours usually causes substantially complete replacement of the haloethyl moiety of the formula Vllle, Xe, VlIld,.or Xd ester with hydrogen. The free'acidis then isolated from the reaction mixture by procedures known to the art. This procedure is also applicable to the production of the free acid form of the formula IXe, Xle, lXd, and Xld compounds from the corresponding haloethyl esters thereof.

As described above, the alkylation of cyclic ketone XV to ketone XXII (Chart B) usually produces a mixture of alpha and beta alkylation products with respect to the Cl-l C E CACOOR or the moiety-Also as described above, those two isomers lead to different final products, alpha leading to the PG -series and'beta leading to the 8-iso-PG -s'eries. If a compound in one or the other of those series is preferred, there are two methods for favoring production of the preferred final product.

One' of those methods involves isomerization of the final product of formula Vllle or formula Vllld: Either the alpha isomer of formula Vllle or Vllld, or the beta isomer of formula Vllle' or Vllld is maintained in an inert liquid diluent-in the range of to 80C. and in the presence of a base characterized by its water solution having a pH belowabout 10 until a substantial amount of the isomer has been isomerized to the other isomer, i.e., alpha to beta or beta-to alph-aPreferred bases for this purpose are the alkali metal salts of carboxylic acids, especially alkanoic acids of 2 to 4 carbon atoms, e.g., sodium acetate. Examples of useful inert liquid diluents are alkanols of one to 4 carbon atoms, e.g., ethanol. This reaction at about 25 C.takes about none "to about days. Apparently an equilibrium is es tablished. The mixtures of the two isomers, alpha an beta, are separated from the reaction mixture b known procedures, and then the two isomers are sepa rated from each other by known procedures, for exam ple, chromatography, recrystallization, ora combina tion of those. The less preferred isomer is then sub jected to the same isomerization to produce more 0 the preferred isomer. In this manner, by repeated isom erizations and separations, substantially all of the les preferred isomer of the formula Vllle. or formula Vlllr compound is transformed to more preferred isomer.

The second method for favoring production of a pre ferred final formula Vllle or formula Vllld isomer in volves any one of the intermediates of formulas XVI XXII, XXlll, XXIV, or XXV (Chart B). Either the alpha form or the beta form of one of those intermediates is transformed to a mixture of both isomers by maintaining one or the other isomer, alpha, or beta, in an inert liquid diluent in the presence of a base and in range 0 to C. until a substantial amount of the starting isomer has been isomerized to the other isomer. Preferredbases for this isomerization are alkali metal amides, alkali metal alkoxides, alkali metal hydrides, and .triarylmethyl alkali metals. Especially preferred are alkali metal tert-alkoxides of 4 to 8 carbon atoms, e.g., potassium tert-butoxide. This reaction at about 25 C. proceeds rapidly (1 minute to several hours). Apparently an equilibrium mixture of both isomers is formed, starting with either isomer. The isomer mixtures in the equilibrium mixture thus obtained are isolated by known procedures, and then the two isomers are separated from each other by known procedures, for .example, chromatography. The less preferred isomer is then subjected to the same isomerization to produce more of the preferred isomer. In this manner, by repeated isomerizations and separations, substantially all of the less preferred isomer of any of these intermediates is transformed to the more preferred isomer.

' The final formula Vllle, lXe, Xe, and X13 compounds and Vllld, lXd, Xd, and Xld compounds prepared by the processes of this invention, in free acid form, are transformed to pharmacologically acceptable salts by neutralization with appropriate amounts of the corresponding inorganic or organic base, examples of which correspond to the cations and amines listed above. These transformations are carried out by a variety of procedures known in the art to be generally useful for the preparation of inorganic, i.e., metal of ammonium, salts, amine acid addition salts, and quaternary ammoniumsalts. The choice of procedure dependsin part upon the solubility characteristics of the particular salt to be prepared. In the case of the inorganic salts, it is usually suitable to dissolve the acid in water containing the stoichiometric amount of a hydroxide, carbonate, or bicarbonate corresponding to the inorganic salt desired, For example, such use of sodium hydroxide, sodium carbonate, or sodium bicarbonate gives a solution of the sodium salt. .Evaporation of thewater or addition of a water-miscible solvent of moderate polarity, for example, a lower alkanol or a .lower alkanone, gives the solid inorganic salt if that form is desired.

- To producean amine salt, the formula Vllle, lXe, Xe, Xle, Vllld, lXd, Xd, or Xld acid is dissolved in a suitable solvent of either moderate or low polarity. Examples of the former are ethanol, acetone, and ethyl acetate. Examples of. the latter are diethyl ether and benzene. At least a stoichiometric amount of the amine corresponding to the desired cation is then added to that solution. If the resulting salt does not precipitate, it is usually obtained in solid form by addition of a miscible diluent of low polarity or by evaporation. If the amine is relatively volatile, any excess can easily be removed by evaporation. It is preferred to use stoichiometric amounts of the less volatile amines.

Salts wherein the cation is quaternary ammonium are produced by mixing the formula Vllle, lXe, Xe, XIe, Vllld, lXd, Xd, or Xld acid with the stoichiometric amount of the corresponding quaternary ammonium hydroxide in water solution, followed by evaporation of the water.

The invention can be more fully understood by the following examples and preparations in which the parts are by weight and solvent ratios are by volume unless otherwise specified.

All temperatures are in degrees Centigrade.

NMR spectra are recorded on a Varian A-60 spectrophotometer on deuterochloroform solutions with tetramethylsilane as an internal standard (downfield).

Mass spectra are recorded on an Atlas CH-4 mass spectrometer with a TO-4 source (ionization voltage 70 ev).

For convenience the formulas are given in the natural configuration, it being understood, though that the compounds produced, unless otherwise specified, include the enantiomorphs.

EXAMPLE 1 Racemic PGE methylester (XXXIX) Endo-bicyclo[ 3. 1 .0. ]hexan-3ol-6-carboxylic acid methyl ester A mixture of endo-bicyclo[3.1.0]hex-2-ene-6-carboxylic acid methyl ester (103 g.) and anhydrous diethyl ether (650 ml.) is stirred under nitrogen and cooled to 5 C. A one molar solution (284 ml.) of diborane in tetrahydrofuran is added dropwise during 30 minutes while keeping the temperature below 0 C. The

resulting mixture is then stirred and allowed to warm to 25 C. during 3 hours. Evaporation under reduced pressure gives a residue which is dissolved in 650 ml. of anhydrous diethyl ether. The solution is cooled to 0 C., and 3 normal aqueous sodium hydroxide solution 172 ml.) is added dropwise under nitrogen and with vigorous stirring during minutes, keeping the temperature at 0 to 5 C. Next, 30% aqueous hydrogen peroxide (94 ml.) is added dropwise with stirring during 30 minutes at 0 to 5 C. Then, 500 ml. of saturated aqueous sodium chloride solution is added, and the diethyl ether layer is separated. The aqueous layer is washed with four 200 ml. portions of ethyl acetate, the washings being added to the diethyl ether layer, which is then washed with saturated aqueous sodium chloride 36 solution, dried, and evaporated to give 115 g. of a residue.'This residue is distilled under reduced pressure to give 69 g. of a mixture of the methyl esters of endobicyclo[3.l.0]hexan-3-ol-6-carboxylic acid and endobicyclo[3.l.0]hexan-2-ol-6-carboxylic acid; b.p. 8695 C. at 0.5 mm.

PART A-2 Endo-bicyclol3.1.0]hexan-3-ol-6-carboxylic acid methyl ester tetrahydropyranyl ether The 2-ol and 3-01 mixture (66 g.) obtained according to Part A-l in 66 ml. of dihydropyran is stirred and cooled at l5-20 C. during addition of 3 ml. of anhydrous diethyl ether saturated with hydrogen chloride. The temperature of the mixture is then kept in the range of 20 to 30 C. for 1 hour with cooling, and is then kept at 25 for 15 hours. Evaporation gives a residue which is distilled under reduced pressure to give 66 g. of a mixture of the methyl esters-tetrahydropyranyl ethers of endobicyclo 3. l .0]hexan-3-ol-6-carboxylic acid and endobicyclo 3. 1 .0]hexan- 2-ol-6-carboxylic acid; b.p. 96l04 C. at 0.1 mm.

PART A-3 Endo-6-hydroxymethylbicyclo[3. l .0]hexan-3-ol- 3-tetrahydropyranyl ether A solution of the mixture (69 g.) of products obtained according to Part A-2 in 300 ml. of anhydrous diethyl ether is added dropwise during 45 minutes to a stirred and cooled mixture of lithium aluminum hydride (21 g.) in 1300 ml. of anhydrous diethyl ether XXXlX under nitroge. The resulting mixture is stirred 2 hours at25 C., and is then cooled to 0 C. Ethyl acetate (71 ml.) is added, and the mixture is stirred 15 minutes. Water (235 ml.) is then added, and the diethyl ether layer is separated. The water layer is washed twice with diethyl ether and twice with ethyl acetate. A solution of Rochelle salts is added to the aqueous layer, which is then saturated with sodium chloride and extracted twice with ethyl acetate. All diethyl ether and ethyl acetate solutions are combined, washed with saturated aqueous sodium chloride solution, dried, and evaporated to give 61 g. of a mixture of the 3-tetrahydropyranyl ethers of endo-6-hydroxymethylbicicyl 3. l .0 ]hexan-3-ol and endo-6-hydroxymethylbicyclo[ 3. l .0 ]-hexan-2'-ol.

PART A-4 Endo-bicyclo[ 3. 1 .0]hexan-3-ol-6 -carboxaldehyde 3-tetrahydropyranyl ether A solution of the mixture (34 g.) of products obtained according to Part A-3 in 1000 ml. of acetone is cooled to 10 C. Jones reagent (75 ml. of a solution of 21 g. of chromic anhydride, 60 ml. of water, and 17 ml.

of concentrated sulfuric acid), precooled to 0 C., is added dropwise with stirring during 10 minutes at l0 C. After 10 minutes of additional stirring at 10 C., isopropyl alcohol (35 m1.) is added during minutes, and stirring is continued for minutes. The reaction mixture is then poured into 81. of an ice and water mixture. The resulting mixture is extracted 6 times with dichloromethane. The combined extracts are washed with aqueous sodium bicarbonate solution, dried, and evaporated to give 27 g. of a mixture of the tetrahydropyranyl ethers of endo-bicyclo[3. l .0]hexan 3-ol-6-carboxaldehyde (XL) and endo-bicyclo[3.1 .0]hexan-2-ol- 6-carboxaldehyde.

PART B 3-Hexynyl- 1 -triphenylphosphonium bromide To a solution of 130 g. (0.81 moles) of l-bromo-hex- 3-yne in 250 ml. of benzene is added 236 g. (0.9 moles) of triphenylphosphine. The resulting solution is heated with stirring in a heating bath of 80 C. for 24 hours. Stirring is continued at room temperature for 24 hours, then the reaction mixture is allowed to stand for 48 hours. An oil precipitated. The supernatant solution is decanted, the oil stirred in 200 ml. of benzene. The oil is again allowed to separate and the supernatant solution separated. The oil is dried under vacuum at room temperature, the oil solidifies while drying. The decanted solutions are combined and heated at 80 C. bath temperature for 48 hours, workup as above resulted in a second batch of solid material making a total yield of 210 g. of 3-hexynyl-l-triphenylphosphonium bromide.

PART C Endo-6-Hept-1-en4ynyl-bicyclo[3. 1 .0 ]hexan-3-ol- 3-tetrahydropyranyl ether (XL!) lHPO CHO

105 g. of the phosphonium salt of Part B is stirred in 1200 ml. of dry tetrahydrofuran under a nitrogen atmosphere. The reaction flask is cooled in an ice-methanol bath. 150 ml. of a 15.1% hexane solution of n-butyl lithium is added dropwise. When the addition was complete, stirring is continued for minutes. Then a solution of 42 g. of aldehyde XL in 150 ml. tetrahydrofuran is added dropwise with stirring over a period of 15 minutes.

The ice-methanol bath is replaced by a heating bath and the reaction mixture is heated at 6070C. bath temperature for 3 hours. The reaction mixture is allowed to stand at room temperature overnight. The solvent is removed under reduced pressure. The residue is treated with 500 ml. benzene and filtered; the solid is washed with 500 ml. benzene, the benzene solutions combined and evaporated under reduced pressure. The resulting oil is triturated with 500 ml. of skellysolve Skellysolve (technical hexane), filtered and the resulting solution evaporated under reduced pressure to give 37 g. of a yellow oil. The oil is chromatographed using 1500 g. of silica gel. The column is developed with seven 1500 ml. portions of 1:1 benzene-Skellysolve B, seven 1500 ml. portions of benzene, five 1500 ml. portions of benzene containing 5% ethyl acetate, five 1500 ml. portions of benzene containing 10% ethyl acetate, and three 1500 ml. portions of ethyl acetate. Fractions l2-18 are combined to give a total of 12.9 g. of tetrahydropyranylether XLl as a colorless oil, fractions 19-26 are combined to give a total of 13.5 g. of the corresponding alcohol XLII as a colorless oil.

PART D Endo-6-hept- 1 -en-4-ynyl-bicyclo[ 3. 1.0]hexan-3-0l (XLII) XLl 1 12.8 g. of tetrahydropyranylether XLl is dissolved in 300 ml. of methanol, 600 mg. of oxalic acid is added and the solution heated under reflux for 1.5 hours. The methanol is evaporated under reduced pressure, the resulting residue dissolved in 300 ml. of methylene chloride, washed with ml. of saturated aqueous HaH- CO and dried over'Na SO Evaporation of solvent results in 11.2 g. of crude alcohol XLII. The alcohol is combined with alcohol XLll obtained in Part C and used for Part E without further purification.

PART E Endo-6-heptl -en-4-ynyl-bicyclo[ 3. 1 .0]hexan 3-one (XLlll) A solution of 23.7 g. of alcohol X1. in 720 ml. of acetone is cooled to 5 to 10C. 48 ml. of Jones reagent is added dropwise over a period of 15 minutes maintaining a reaction temperature of 0 to 5C. When the addition is complete, stirring is continued for 10 minutes at 5 C. 24 ml. of isopropanol is added and stirring continued for 10 minutes. The green solution is poured into 5 liters of water and the aqueous solution extracted with five 1 liter portions of methylene chloride. The combined extracts are washed with 750 m1. of saturated aqueous NaHCO two 750 m1. portions of saturated aqueous NaCl and dried over Na SO Evaporation of solvent under reduced pressure yields 18.2 g. of a brown oil which is chromatographed using 800 g. of silica gel. The column is developed with four 800 ml. portions of Skellysolve B containing 2.5% ethyl acetate and twelve 800 ml. portions of Skellysolve B containing 5% ethyl acetate. Fractions 9-14 are combined to yield 5.3 g. of ketone XLIII as a colorless oil.

NMR: 1 H at 5.4 5.98 (multiplet), 1 H at 4.75.28 (multiplet), 2 H at 2.75 3.08; 9 H at 14-2758, 3 H at 

1. A RACEMIC MIXTURE OF A COMPOUND OF THE FORMULA:
 2. A racemic mixture according to claim 1 wherein R1 is hydrogen or alkyl or one to 4 carbon atoms, inclusive, or a pharmacologically acceptable salt thereof when R1 is hydrogen.
 3. A racemic mixture according to claim 2 wherein the side-chain hydroxy is in S configuration.
 4. A racemic mixture according to claim 3 wherein n is one.
 5. A racemic mixture according to claim 4 wherein A is trimethylene.
 6. A racemic mixture according to claim 5 wherein R2 is ethyl.
 7. Racemic PGF3 , a racemic mixture according to claim 6 wherein R1 is hydrogen.
 8. AN OPTICALLY ACTIVE COMPOUND OF THE FORMULA:
 9. An optically active compound according to claim 8 wherein the side-chain hydroxy is in S configuration, and wherein R1 is hydrogen or alkyl of one to 4 carbon atoms, or a pharmacologically acceptable salt thereof when R1 is hydrogen.
 10. An optically active compound according to claim 9 wherein R2 is ethyl and b is one.
 11. An optically active compound according to claim 10 wherein Z is ethylene substituted with 2 fluoro on the carbon atom alpha to the carboxylate function.
 12. An optically active compound according to claim 11 wherein R3 and R4 are hydrogen.
 13. An optically active compound according to claim 11 wherein R3 is alkyl of one to 4 carbon atoms, inclusive, and R4 is hydrogen. 